Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Net Income (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Net Income data on record, last reported at -$5.3 million in Q3 2025.

  • For Q3 2025, Net Income fell 17.81% year-over-year to -$5.3 million; the TTM value through Sep 2025 reached -$19.4 million, up 10.46%, while the annual FY2024 figure was -$20.4 million, 9.51% up from the prior year.
  • Net Income reached -$5.3 million in Q3 2025 per GANX's latest filing, up from -$5.8 million in the prior quarter.
  • Across five years, Net Income topped out at $12.7 million in Q4 2022 and bottomed at -$8.1 million in Q2 2024.
  • Average Net Income over 5 years is -$3.4 million, with a median of -$4.6 million recorded in 2022.
  • The widest YoY moves for Net Income: up 238.89% in 2021, down 554.57% in 2021.
  • A 5-year view of Net Income shows it stood at $4.4 million in 2021, then skyrocketed by 189.09% to $12.7 million in 2022, then crashed by 139.58% to -$5.0 million in 2023, then grew by 24.84% to -$3.8 million in 2024, then crashed by 40.23% to -$5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$5.3 million in Q3 2025, -$5.8 million in Q2 2025, and -$4.5 million in Q1 2025.